Durable Goods (Jun F) -9.4% vs 9.3% Prior, Ex-Trans 0.2% vs 0.2%
Campbell, CA-based semiconductor company Arteris , Inc. (NASDAQ:AIP), currently valued at $309 million, disclosed the resignation of board member Isabelle F. Geday, effective as of March 27, 2025. The announcement, made in a recent SEC filing, stated that Geday’s departure is due to personal reasons and is not related to any disagreements with the company’s operations, policies, or practices. According to InvestingPro data, this development comes as the stock has declined 26% year-to-date, though analysts maintain a Strong Buy consensus on the shares.
Geday has been serving on the Arteris board since 2020, and her contribution has been recognized as exemplary by the company. In light of her unexpected resignation, the Arteris board has approved the accelerated vesting of Geday’s annual restricted stock unit (RSU) award. The award consists of 19,287 RSUs that were granted at the company’s 2024 annual meeting of stockholders under the Non-Employee Director Compensation Policy. These RSUs were originally set to vest on the earlier of June 4, 2025, or the date of the company’s 2025 annual meeting of stockholders. InvestingPro analysis reveals the company maintains impressive gross profit margins of nearly 90% and holds more cash than debt on its balance sheet.
The information in this article is based on a press release statement from Arteris, Inc. The company, incorporated in Delaware and with a fiscal year ending on December 31, specializes in semiconductors and related devices. Arteris has not indicated any immediate plans for replacing Geday on the board.
This corporate governance update comes as Arteris continues to navigate the competitive semiconductor industry, where board composition and executive leadership are critical for strategic decision-making and oversight. The company’s stock is publicly traded on The Nasdaq Stock Market under the ticker symbol AIP.
In other recent news, Arteris, Inc. has seen significant developments that are drawing attention from analysts. Jefferies analyst Blayne Curtis increased the company’s price target to $11.00, up from $7.00, while maintaining a Hold rating. This adjustment is based on Arteris’ advancements in the microcontroller unit (MCU) market, including a notable win at IFX and the introduction of the FlexGen solution, which could enhance average selling prices by 30%. However, Jefferies remains cautious due to lower-than-expected 2025 guidance, awaiting more evidence of improved execution in MCU and FlexGen sales before considering a more positive stance.
Meanwhile, Northland analysts have raised their price target for Arteris to $16.00 from $14.00, maintaining an Outperform rating. This decision follows Arteris’ revenue meeting expectations and the launch of the new FlexGen product, which is expected to boost future revenues. The company reported bookings of approximately $33.6 million for the quarter, with a book-to-bill ratio of 2.2:1, and FlexNoC 5 contributing significantly to interconnect licenses. Northland’s revised target reflects confidence in Arteris’ market position and the potential impact of FlexGen on financial performance, with 13 customers currently evaluating the new product.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.